Say goodbye to insulin? New device controls blood sugar

Mice treated with a novel electronic implant experienced significant reductions in both blood glucose levels and body weight, according to research published in Science. The device, developed by a team led by Martin Fussenegger at ETH Zurich’s Department of Biosystems Science and Engineering in Basel, utilizes an electrically powered catalyst rather than traditional biological agents to manage Type 2 diabetes symptoms.

How the electronic catalyst functions

The system addresses the limitations of insulin therapy, which facilitates glucose uptake into muscle cells but fails to resolve chronic energy surpluses that lead to fat storage. By converting excess glucose directly into gluconate, the implant prevents this metabolic surplus from being stored as tissue fat. The resulting gluconate is subsequently excreted through urine, offering a mechanism that targets the root cause of obesity-linked diabetes without relying on cellular metabolism.

Central to the design is a catalyst composed entirely of inorganic materials, eliminating the need for cells or enzymes. This structure consists of graphite felt embedded with gold nanoclusters, further decorated with platinum particles. Fussenegger noted that the nanostructured surface was developed by the team and demonstrated excellent biocompatibility during experimental phases. An electronic control unit, housed within a 3D-printed casing, manages the process, receiving power wirelessly at 13.56 MHz—a frequency designated for industrial, scientific, and medical applications.

Closed-loop regulation and safety

The implant operates through a closed-loop system integrated with standard glucose sensors similar to those worn on the upper arm by patients. When post-meal blood sugar levels rise beyond a set threshold, the sensor transmits a signal via Bluetooth to a smartphone or smartwatch. This external device then activates the catalyst to begin electrical conversion of glucose. Once levels return to the desired range, the system automatically deactivates, a feature designed to prevent hypoglycemia.

Laboratory tests confirmed the catalyst's efficacy in a five-liter reservoir of nutrient solution, approximating human blood volume. Subsequent trials in diabetic mice showed precise regulation of blood sugar, reliable operation over six weeks, and good tolerance of the implant. "The system operates at a very low voltage, and our experiments showed no evidence of tissue damage from either electrical or thermal effects," stated Professor Fussenegger.

Future development and commercial viability

Fussenegger describes the approach as a paradigm shift from conventional pharmacological treatments toward scalable, electronically controlled therapies compatible with digital environments like the Internet of Things. "For decades, we have treated diabetes by telling the body how to manage glucose. We are now showing that we can take control of glucose directly, using electronics rather than drugs," he said. He emphasized that the catalyst remains inactive unless glucose levels exceed specific limits.

The research team has not yet conducted human trials but plans to advance the technology into a medical device. Because the core mechanism functions without biological components, regulatory and manufacturing hurdles may be lower compared to gene-based therapies. Additionally, essential elements such as external controllers and wireless power transmission units are already commercially available, potentially streamlining the path to market.

Journal reference: Maity, D., et al. (2026). Wireless electrocatalytic closed-loop system for drug-free management of diabesity. Science. DOI: 10.1126/science.ady8560. https://www.science.org/doi/10.1126/science.ady8560